Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study
BackgroundPartial dopamine D2 receptor agonists are used for psychotic symptoms in adults with schizophrenia spectrum disorders. Recently, interest surged for partial dopamine D2 receptor agonists in substance use disorders (SUDs). Since it is believed that SUDs decrease the efficacy of pharmacother...
Main Authors: | Ginevra Lombardozzi, Giada Trovini, Emanuela Amici, Georgios D. Kotzalidis, Filippo Perrini, Valeria Giovanetti, Alessandro Di Giovanni, Sergio De Filippis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1321233/full |
Similar Items
-
Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
by: Jun Ishigooka, et al.
Published: (2020-06-01) -
Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
by: Yusuke Arai, et al.
Published: (2023-03-01) -
Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
by: Rina Yokoi, et al.
Published: (2023-08-01) -
A comprehensive evaluation of adverse childhood experiences, social–emotional impairments, and neurodevelopmental disorders in cannabis-use disorder: Implications for clinical practice
by: Giada Trovini, et al.
Published: (2023-01-01) -
Impressive Response with Brexpiprazole in Ekbom’s syndrome
by: J. Hsiao, et al.
Published: (2022-06-01)